BJDX

Announcements

Nothing here yet

Daily updates

• Bluejay Diagnostics reported baseline SYMON-II pivotal-study data from 777 evaluable sepsis patients, including 140 deaths at 28 days, ahead of a planned FDA 510(k) submission.Oct 6, 2026

FDA designations

Nothing here yet

News

• Bluejay Diagnostics completes enrollment in the SYMON-II multicenter clinical validation studyJul 21, 2026
• Bluejay Diagnostics completed enrollment in SYMON-II pivotal trialApr 7, 2026